| Value | ₹154.2 Cr |
|---|---|
| Execution period | 3 years |
NSE filing, NSE: DRREDDY. Summary written from the filing by ALFA Finder's alert engine.
Dr. Reddy's Laboratories Ltd: key numbers
- Share price
- ₹1,345.00
- Market cap
- ₹1,12,264 Cr
- Revenue (annual)
- ₹33,700 Cr
- Net profit (annual)
- ₹4,196 Cr
- P/E (TTM)
- 40.1×Sector 46.1×
- Promoter holding
- 26.63%-0.01% QoQ
- FII holding
- 20.30%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dr. Reddy's Laboratories Ltd
All →Dr. Reddy's Laboratories Business Update
Dr Reddy's says USFDA closed its PAI and GMP inspection at Srikakulam FTO-SEZ Process Unit-02 with VAI classification. The outcome is closed with no monetary penalty.
Dr. Reddy's Laboratories Earnings Call Transcript: Key Takeaways
Revenue declined 1.5% YoY as lower Revlimid sales in North America offset strong double-digit growth in base business and emerging markets.
- Call
- Guides 25% growth
Dr. Reddy's Laboratories Management Change
Dr Reddy's appointed Akhil Ravi as Head API and Services and Senior Management Personnel, effective 13 November 2026. Ravi is the son-in-law of co-chairman G V Prasad.
Dr. Reddy's Laboratories Investor Presentation: Key Takeaways
Q2FY27 revenue ₹8,671 Cr (-1.5% YoY), EBITDA ₹1,783 Cr (20.6%), PAT ₹925 Cr (-36% YoY). Management stresses double-digit base-business growth excluding lenalidomide in North America.
Dr. Reddy's Laboratories Q2 FY27 Results: Net Profit ₹913.2 Cr, Down 31.7% YoY
Dr. Reddy's Laboratories Ltd reported revenue from operations of ₹8,698 Cr (-1.5% YoY) and net profit of ₹913.2 Cr (-31.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹913.2 Cr · -31.7% YoY
Dr. Reddy's Laboratories Other Announcement
Dr. Reddy's Laboratories Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, including notes on significant beneficial ownership.
Other employee stock options announcements
All →Strides Pharma Science Employee Stock Options
Strides Pharma allotted 7,500 equity shares to an employee exercising options under the Strides ESOP 2016 Plan. Paid-up capital rises to 92,180,214 shares.
Shaily Engineering Plastics Employee Stock Options
Shaily Engineering Plastics allotted 1,300 equity shares to employees on exercise of ESOPs at Rs. 732 per share under its 2019 plan. Issued paid-up capital rises to 4,59,96,548 shares of Rs. 2 each.
Info Edge (India) Employee Stock Options
Info Edge's employee stock option trust sold 1,439 shares on 26 October 2026 under the ESOP scheme. The disposal reduces the trust's holding to 410,707 shares.
Motilal Oswal Financial Services Employee Stock Options
Motilal Oswal Financial Services granted 2,20,000 stock options to eligible employees under its ESOP Scheme X. No exercise price or monetary value is disclosed.
Borosil Employee Stock Options
Borosil granted 7,23,200 employee stock options at Rs 192.8 each under its 2020 scheme. Options vest in three tranches over three years.
- Execution
- Vesting over 3 years from grant date
Natco Pharma Employee Stock Options
Natco Pharma's insiders, including promoters and directors, were allotted equity shares. This allotment increases their total shareholding in the company.
- Value
- ₹144.2 Cr